Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population

Jean B. Nachega, Alice J. Hsu, Olalekan A. Uthman, Anne Spinewine, Paul Pham

Research output: Contribution to journalArticle

Abstract

It is estimated that by 2015 more than half of all HIV-infected individuals in the United States will be 50 years of age or older. As this population ages, the frequency of non-AIDS related comorbidities increases, which includes cardiovascular, metabolic, gastrointestinal, genitourinary and psychiatric disorders. As a result, medical management of the aging HIV population can be complicated by polypharmacy and higher pill burden, leading to poorer antiretroviral therapy (ART) adherence. Adherence to ART is generally better in older populations when compared to younger populations; however, cognitive impairment in elderly patients can impair adherence, leading to worse treatment outcomes. Practical monitoring tools can improve adherence and increase rates of viral load suppression. Several antiretroviral drugs exhibit inhibitory and/or inducing effects on cytochrome P450 isoenzymes, which are responsible for the metabolism of many medications used for the treatment of comorbidities in the aging HIV population. The combination of ART with polypharmacy significantly increases the chance of potentially serious drug-drug interactions (DDIs), which can lead to drug toxicity, poorer ART adherence, loss of efficacy of the coadministered medication, or virologic breakthrough. Increasing clinicians awareness of common DDIs and the use of DDI programs can prevent coadministration of potentially harmful combinations in elderly HIV-infected individuals. Well designed ART adherence interventions and DDI studies are needed in the elderly HIV population.

Original languageEnglish (US)
JournalAIDS
Volume26
Issue numberSUPPL.1
DOIs
StatePublished - Jul 31 2012

Fingerprint

Drug Interactions
HIV
Drug Therapy
Population
Polypharmacy
Pharmaceutical Preparations
Comorbidity
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Viral Load
Cytochrome P-450 Enzyme System
Isoenzymes
Psychiatry

Keywords

  • adherence
  • aging
  • antiretroviral therapy
  • drug-drug interactions

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Nachega, J. B., Hsu, A. J., Uthman, O. A., Spinewine, A., & Pham, P. (2012). Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. AIDS, 26(SUPPL.1). https://doi.org/10.1097/QAD.0b013e32835584ea

Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. / Nachega, Jean B.; Hsu, Alice J.; Uthman, Olalekan A.; Spinewine, Anne; Pham, Paul.

In: AIDS, Vol. 26, No. SUPPL.1, 31.07.2012.

Research output: Contribution to journalArticle

Nachega, JB, Hsu, AJ, Uthman, OA, Spinewine, A & Pham, P 2012, 'Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population', AIDS, vol. 26, no. SUPPL.1. https://doi.org/10.1097/QAD.0b013e32835584ea
Nachega, Jean B. ; Hsu, Alice J. ; Uthman, Olalekan A. ; Spinewine, Anne ; Pham, Paul. / Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. In: AIDS. 2012 ; Vol. 26, No. SUPPL.1.
@article{7c36ef394a30468fae73b49600458d17,
title = "Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population",
abstract = "It is estimated that by 2015 more than half of all HIV-infected individuals in the United States will be 50 years of age or older. As this population ages, the frequency of non-AIDS related comorbidities increases, which includes cardiovascular, metabolic, gastrointestinal, genitourinary and psychiatric disorders. As a result, medical management of the aging HIV population can be complicated by polypharmacy and higher pill burden, leading to poorer antiretroviral therapy (ART) adherence. Adherence to ART is generally better in older populations when compared to younger populations; however, cognitive impairment in elderly patients can impair adherence, leading to worse treatment outcomes. Practical monitoring tools can improve adherence and increase rates of viral load suppression. Several antiretroviral drugs exhibit inhibitory and/or inducing effects on cytochrome P450 isoenzymes, which are responsible for the metabolism of many medications used for the treatment of comorbidities in the aging HIV population. The combination of ART with polypharmacy significantly increases the chance of potentially serious drug-drug interactions (DDIs), which can lead to drug toxicity, poorer ART adherence, loss of efficacy of the coadministered medication, or virologic breakthrough. Increasing clinicians awareness of common DDIs and the use of DDI programs can prevent coadministration of potentially harmful combinations in elderly HIV-infected individuals. Well designed ART adherence interventions and DDI studies are needed in the elderly HIV population.",
keywords = "adherence, aging, antiretroviral therapy, drug-drug interactions",
author = "Nachega, {Jean B.} and Hsu, {Alice J.} and Uthman, {Olalekan A.} and Anne Spinewine and Paul Pham",
year = "2012",
month = "7",
day = "31",
doi = "10.1097/QAD.0b013e32835584ea",
language = "English (US)",
volume = "26",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL.1",

}

TY - JOUR

T1 - Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population

AU - Nachega, Jean B.

AU - Hsu, Alice J.

AU - Uthman, Olalekan A.

AU - Spinewine, Anne

AU - Pham, Paul

PY - 2012/7/31

Y1 - 2012/7/31

N2 - It is estimated that by 2015 more than half of all HIV-infected individuals in the United States will be 50 years of age or older. As this population ages, the frequency of non-AIDS related comorbidities increases, which includes cardiovascular, metabolic, gastrointestinal, genitourinary and psychiatric disorders. As a result, medical management of the aging HIV population can be complicated by polypharmacy and higher pill burden, leading to poorer antiretroviral therapy (ART) adherence. Adherence to ART is generally better in older populations when compared to younger populations; however, cognitive impairment in elderly patients can impair adherence, leading to worse treatment outcomes. Practical monitoring tools can improve adherence and increase rates of viral load suppression. Several antiretroviral drugs exhibit inhibitory and/or inducing effects on cytochrome P450 isoenzymes, which are responsible for the metabolism of many medications used for the treatment of comorbidities in the aging HIV population. The combination of ART with polypharmacy significantly increases the chance of potentially serious drug-drug interactions (DDIs), which can lead to drug toxicity, poorer ART adherence, loss of efficacy of the coadministered medication, or virologic breakthrough. Increasing clinicians awareness of common DDIs and the use of DDI programs can prevent coadministration of potentially harmful combinations in elderly HIV-infected individuals. Well designed ART adherence interventions and DDI studies are needed in the elderly HIV population.

AB - It is estimated that by 2015 more than half of all HIV-infected individuals in the United States will be 50 years of age or older. As this population ages, the frequency of non-AIDS related comorbidities increases, which includes cardiovascular, metabolic, gastrointestinal, genitourinary and psychiatric disorders. As a result, medical management of the aging HIV population can be complicated by polypharmacy and higher pill burden, leading to poorer antiretroviral therapy (ART) adherence. Adherence to ART is generally better in older populations when compared to younger populations; however, cognitive impairment in elderly patients can impair adherence, leading to worse treatment outcomes. Practical monitoring tools can improve adherence and increase rates of viral load suppression. Several antiretroviral drugs exhibit inhibitory and/or inducing effects on cytochrome P450 isoenzymes, which are responsible for the metabolism of many medications used for the treatment of comorbidities in the aging HIV population. The combination of ART with polypharmacy significantly increases the chance of potentially serious drug-drug interactions (DDIs), which can lead to drug toxicity, poorer ART adherence, loss of efficacy of the coadministered medication, or virologic breakthrough. Increasing clinicians awareness of common DDIs and the use of DDI programs can prevent coadministration of potentially harmful combinations in elderly HIV-infected individuals. Well designed ART adherence interventions and DDI studies are needed in the elderly HIV population.

KW - adherence

KW - aging

KW - antiretroviral therapy

KW - drug-drug interactions

UR - http://www.scopus.com/inward/record.url?scp=84863852380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863852380&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e32835584ea

DO - 10.1097/QAD.0b013e32835584ea

M3 - Article

VL - 26

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - SUPPL.1

ER -